Skip to page content
Back to overview

Jun 25, 2019

Urinary marker for bladder cancer detection

Life Sciences, Diagnostics/Biomarker

  • The focal adhesion protein LASP-1 is a novel and simply detectable marker for urothelial carcinoma of the bladder (UCB)
  • LASP-1 overcomes the limitation of currently used cystoscopy and urine cytology for diagnosis of UCB
  • LASP-1 is detected in voided urine sediment of bladder cancer patients and is combinable with a second marker to further raise specificity/sensitivity

Your contact

Dr. Katrin Bercht

E-Mail:
kbercht@baypat.de
Phone:
+49 (0) 89 5480177 - 16
Reference Number:
B71211

Challenge

Urothelial carcinoma of the bladder (UCB) is the most common genitourinary cancer. ­Diagnosis of UCB currently relies on cystoscopy and urine cytology. Both examination methods have limitations. Urethrocystoscopy is expensive, invasive, and associated with ­postcystoscopy pain and/or risk of urinary infection. Cystoscopy has tendency to miss flat lesions, such as ­carcinoma in situ, while urine cytology is prone to missing ­well-differentiated low-grad ­lesions. After transurethral resection and adjuvant chemo- or immunotherapy, ­patients ­require regular follow-up cystoscopies due to the high recurrence rate, making TCC the most ­socioeconomically expensive tumor entity.

Innovation

The LIM and SH3 (LASP)-1 protein is a focal adhesion protein involved in numerous ­biological and pathological processes and has been linked to the oncogenesis of bladder cancer. The protein is detected in voided urine sediment of bladder cancer patients and is described as a promising new marker for bladder cancer that overcomes the limitations of the current ­diagnostic tests for UCB.

Commercial Opportunities

  • Convenient marker for detection and especially follow-up examination of UCB simply detectable in spontaneously voided urine
  • Combinable with a second marker to further raise specificity/sensitivity

Development Status

In a cohort of 246 patients

  • the diagnostic accuracy of LASP1 detection was confirmed,
  • cut-off values were determined to handle erythrocyte/leukocyte
  • contamination (although in follow up studies hematuria isn’t a major issue),
  • a stabilization protocol for sample shipment was established

References

  • Reference 1

    Ardelt et al., Urol Oncol. 2013; 31(8): 1591-1598

  • Reference 2

    Butt et al., Biomark.Med. 2017; 11(4): 347-357

Interested? Get in touch!

Contact a specific team member for individual topics via the Team section or simply use our contact form. You can also click on the button and drop us a line.